Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Lipozem is reshaping how people approach weight loss, and here we provide a comprehensive review supported by real consumer insights ... setting it apart from supplements offering superficial, ...

In the pop culture of the investing community, Hims & Hers Health, Inc. (NYSE:HIMS) (Hims for short) has been described in all manner of ways: The ED pill ... hair loss or GLP-1s for weight ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

And there are some supplements that can help with weight loss, too. As always, you should check with your physician before taking any supplement. One popular and affordable supplement that has ...

Hims offers several products to help prevent and treat hair loss. Some are only available with a prescription. We break these products down for you in our review ... take one pill a day—but ...

The U.S. Food and Drug Administration wants bulk production of copycat versions of popular weight-loss drugs to stop ... The Wall Street Journal writes. Hims & Hers Health will keep offering ...

"I was skeptical at first, but my wife convinced me to try it. I never expected to lose three belt sizes in just six weeks. I didn't change my diet, didn't start exercising like crazy-I just followed ...